AR096152A1 - Derivados de purina - Google Patents
Derivados de purinaInfo
- Publication number
- AR096152A1 AR096152A1 ARP140101783A ARP140101783A AR096152A1 AR 096152 A1 AR096152 A1 AR 096152A1 AR P140101783 A ARP140101783 A AR P140101783A AR P140101783 A ARP140101783 A AR P140101783A AR 096152 A1 AR096152 A1 AR 096152A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- azaspiro
- azetidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: A es CH₂, CH₂CH₂, CH₂CO o está ausente; R¹ es tert-butilo, tert-butilamino, 2,2-dimetilpropiloxi o halógeno; R² y R³ junto con el átomo de nitrógeno, al que están unidos, forman un pirrolidinilo, pirrolidinilo sustituido, tiazolidinilo, alquilpiperazinilo, 2-oxa-7-azaespiro[3.4]-octilo, 2-oxa-6-azaespiro[3.3]heptilo, azetidinilo, azetidinilo sustituido, 2,2-dioxo-2l⁶-tia-6-azaespiro[3.3]-heptilo o halo-5-azaespiro[2.4]heptilo, dicho pirrolidinilo sustituido es pirrolidinilo sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre halógeno, hidroxilo, alquilo, hidroxialquilo, ciano, alquilcarbonil-amino, alquilcarboniloxi y haloalquilo y dicho azetidinilo sustituido es azetidinilo sustituido por uno o dos sustituyentes elegidos entre halógeno, hidroxilo, alquilo y haloalquilo; y R⁴ es hidrógeno, fenilo, halofenilo, alquilfenilo, haloalquilfenilo, piridinilo, halopiridinilo, cicloalquilo, alquilo, alquiloxadiazolilo, oxolanilo, alquiltetrazolilo, alcoxi, alquilsulfonilfenilo, haloalquilo, alcoxifenilo, dioxotietanilo, cicloalquiltetrazolilo, haloalquil-1H-pirazolilo o cicloalquilalquiltetrazolilo; o una sal o éster farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13166293 | 2013-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096152A1 true AR096152A1 (es) | 2015-12-09 |
Family
ID=48190399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101783A AR096152A1 (es) | 2013-05-02 | 2014-04-30 | Derivados de purina |
Country Status (32)
Country | Link |
---|---|
US (1) | US9505762B2 (es) |
EP (1) | EP2991987B1 (es) |
JP (1) | JP6513636B2 (es) |
KR (2) | KR20210145303A (es) |
CN (1) | CN105209466B (es) |
AR (1) | AR096152A1 (es) |
AU (1) | AU2014261585B2 (es) |
BR (1) | BR112015027396B1 (es) |
CA (1) | CA2903588C (es) |
CL (1) | CL2015003195A1 (es) |
CR (1) | CR20150511A (es) |
DK (1) | DK2991987T3 (es) |
EA (1) | EA027497B1 (es) |
ES (1) | ES2680935T3 (es) |
HK (1) | HK1214245A1 (es) |
HR (1) | HRP20181141T1 (es) |
HU (1) | HUE039589T2 (es) |
IL (1) | IL242160B (es) |
LT (1) | LT2991987T (es) |
MA (1) | MA38460B1 (es) |
MX (1) | MX2015014757A (es) |
PE (1) | PE20151977A1 (es) |
PH (1) | PH12015502471B1 (es) |
PL (1) | PL2991987T3 (es) |
PT (1) | PT2991987T (es) |
RS (1) | RS57461B1 (es) |
SG (1) | SG11201509014UA (es) |
SI (1) | SI2991987T1 (es) |
TR (1) | TR201809417T4 (es) |
TW (1) | TWI649322B (es) |
UA (1) | UA116654C2 (es) |
WO (1) | WO2014177490A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028123B1 (ru) | 2013-05-02 | 2017-10-31 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 |
UA116395C2 (uk) | 2013-09-06 | 2018-03-12 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ |
PE20170683A1 (es) * | 2014-11-07 | 2017-05-22 | Hoffmann La Roche | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2 |
FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017220544A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
EP3475281A1 (en) | 2016-06-23 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
KR20230062680A (ko) * | 2016-06-23 | 2023-05-09 | 에프. 호프만-라 로슈 아게 | 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체 |
JP7090037B2 (ja) | 2016-06-23 | 2022-06-23 | エフ.ホフマン-ラ ロシュ アーゲー | 新規な[1,2,3]トリアゾロ[4,5-d]ピリミジン誘導体 |
EP3388432A1 (en) * | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
CN115246832B (zh) * | 2022-06-15 | 2024-05-24 | 深圳湾实验室 | 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057517A (en) * | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
NZ225447A (en) * | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
JP2005531520A (ja) | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換2,3−ジフェニルピリジン類 |
US20030191973A1 (en) * | 2002-04-04 | 2003-10-09 | Johnson Carolynn Rae | Temporary user suspension of automatic shutdown |
DE10219435A1 (de) | 2002-05-02 | 2003-11-13 | Bayer Cropscience Ag | Substituierte Pyrazolo-pyrimidin-4-one |
US7335654B2 (en) * | 2002-08-08 | 2008-02-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
US20100227845A1 (en) | 2007-10-18 | 2010-09-09 | Zhicai Wu | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
EP2279188B1 (en) * | 2008-05-30 | 2015-01-28 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
WO2010019762A1 (en) * | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Purine compounds as cannabinoid receptor blockers |
WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
UA111640C2 (uk) | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
EP2870139B1 (en) | 2012-07-04 | 2016-06-15 | F.Hoffmann-La Roche Ag | Novel adamantyl derivatives as cannabinoid receptor 2 agonists |
UA114657C2 (uk) | 2012-12-07 | 2017-07-10 | Ф. Хоффманн-Ля Рош Аг | Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2 |
EP3357918A1 (en) | 2012-12-07 | 2018-08-08 | F. Hoffmann-La Roche AG | Novel pyridine derivatives |
CN104837830B (zh) | 2012-12-07 | 2018-07-20 | 霍夫曼-拉罗奇有限公司 | 作为cb2受体激动剂的吡嗪衍生物 |
MA38218A1 (fr) | 2012-12-07 | 2016-04-29 | Hoffmann La Roche | Pyridine-2-amides utiles comme agonistes de cb2 |
CA2897513C (en) | 2013-03-07 | 2021-03-16 | F. Hoffmann-La Roche Ag | Pyrazol derivatives |
-
2014
- 2014-04-28 WO PCT/EP2014/058545 patent/WO2014177490A1/en active Application Filing
- 2014-04-28 LT LTEP14719767.7T patent/LT2991987T/lt unknown
- 2014-04-28 MA MA38460A patent/MA38460B1/fr unknown
- 2014-04-28 JP JP2016511024A patent/JP6513636B2/ja active Active
- 2014-04-28 BR BR112015027396-3A patent/BR112015027396B1/pt active IP Right Grant
- 2014-04-28 TR TR2018/09417T patent/TR201809417T4/tr unknown
- 2014-04-28 MX MX2015014757A patent/MX2015014757A/es active IP Right Grant
- 2014-04-28 PE PE2015002327A patent/PE20151977A1/es active IP Right Grant
- 2014-04-28 AU AU2014261585A patent/AU2014261585B2/en active Active
- 2014-04-28 CA CA2903588A patent/CA2903588C/en active Active
- 2014-04-28 UA UAA201511398A patent/UA116654C2/uk unknown
- 2014-04-28 PL PL14719767T patent/PL2991987T3/pl unknown
- 2014-04-28 DK DK14719767.7T patent/DK2991987T3/en active
- 2014-04-28 CN CN201480024472.9A patent/CN105209466B/zh active Active
- 2014-04-28 HU HUE14719767A patent/HUE039589T2/hu unknown
- 2014-04-28 EP EP14719767.7A patent/EP2991987B1/en active Active
- 2014-04-28 RS RS20180796A patent/RS57461B1/sr unknown
- 2014-04-28 SG SG11201509014UA patent/SG11201509014UA/en unknown
- 2014-04-28 PT PT147197677T patent/PT2991987T/pt unknown
- 2014-04-28 SI SI201430796T patent/SI2991987T1/en unknown
- 2014-04-28 EA EA201591976A patent/EA027497B1/ru not_active IP Right Cessation
- 2014-04-28 KR KR1020217037730A patent/KR20210145303A/ko not_active Application Discontinuation
- 2014-04-28 ES ES14719767.7T patent/ES2680935T3/es active Active
- 2014-04-28 KR KR1020157031315A patent/KR102330794B1/ko active IP Right Grant
- 2014-04-30 AR ARP140101783A patent/AR096152A1/es active IP Right Grant
- 2014-04-30 TW TW103115666A patent/TWI649322B/zh active
-
2015
- 2015-09-29 CR CR20150511A patent/CR20150511A/es unknown
- 2015-10-19 IL IL242160A patent/IL242160B/en active IP Right Grant
- 2015-10-26 PH PH12015502471A patent/PH12015502471B1/en unknown
- 2015-10-26 US US14/923,177 patent/US9505762B2/en active Active
- 2015-10-30 CL CL2015003195A patent/CL2015003195A1/es unknown
-
2016
- 2016-02-23 HK HK16102012.2A patent/HK1214245A1/zh unknown
-
2018
- 2018-07-18 HR HRP20181141TT patent/HRP20181141T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096152A1 (es) | Derivados de purina | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR094857A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
AR095721A1 (es) | Derivados de piridina | |
ES2662444T3 (es) | Derivado de piridina | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
AR081072A1 (es) | Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia | |
AR092684A1 (es) | Compuestos de sulfonamida sustituidos | |
AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
AR093804A1 (es) | Derivados de pirazina agonistas de receptores cb2 | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR092973A1 (es) | Benzamidas | |
AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
RS54183B1 (en) | PIRAZOLE DERIVATIVES | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR104880A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |